- Cohort B: In addition to the oncolytic virus patients will also receive tremelimumab 75 mg and durvalumab 1500 mg as intravenous infusions beginning on Day 1 followed by q28days for 4 doses with subsequent continuation of the durvalumab alone until off-treatment criteria are met.